In this study, we demonstrate that SIGLEC12 expression is highly increased at the early stage of BCa due to promoter hypomethylation and is associated with the immune context and oncogenic pathways in the tumor microenvironment, as well as drug resistance. The gene discussed is SIGLEC12; the disease is neoplasm.